ClinicalTrials.gg
CompletedNCT00160173Updated Sep 13, 2022

Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy

A Phase 4 interventional study of Estrogel and Placebo in Postmenopausal Symptoms, sponsored by ASCEND Therapeutics. Completed at 109 sites in United States. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-09-13.

Sponsored by ASCEND Therapeutics · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Dec 2004, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
221
Allocation
Randomized
Ages
45 Years to 65 Years
Sex
Female
01

Study summary

This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.

Read the detailed description

The primary objective of this study was to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause by comparing the efficacy of 0.9 g and 1.25 g EstroGel® 0.03% doses with placebo. Effects on symptoms of vulvar and vaginal atrophy were assessed as secondary efficacy parameters.

02

Conditions studied

  • Postmenopausal Symptoms

Keywords

  • Post menopausal vasomotor symptoms
03

In context

Lead sponsor

ASCEND Therapeutics is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
45 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women 45-65 years
  • naturally or surgically
  • experiencing hot flushes

Exclusion criteria

Exclusion Criteria:

  • to estrogen replacement therapy
  • pregnancy or lactating
  • abnormal PAP smear
  • history/suspected cervical, uterine, adrenal, pituitary, breast or ovarian
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
221 participants (actual)

Study arms

  • Experimental
    EstroGel® Gel 0.9 grams 0.03%

    0.9 g of EstroGel® 0.03% applied to one arm and 1.25 g of placebo gel applied on the other arm once daily for 12 weeks.

    Drug: Estrogel

  • Experimental
    EstroGel® Gel 1.25 grams 0.03%

    1.25 g of EstroGel® 0.03% applied to one arm and 0.9 g of placebo gel applied on the other arm once daily for 12 weeks.

    Drug: Estrogel

  • Placebo comparator
    Placebo Gel

    0.9 g of placebo gel applied to one arm and 1.25 g of placebo gel applied on the other arm once daily for 12 weeks.

    Other: Placebo

Interventions

06

Study locations

109 sites
  • Site 112
    Birmingham, Alabama, United States
  • Site 74
    Mobile, Alabama, United States
  • Site 20
    Montgomery, Alabama, United States
  • Site 34
    Tucson, Arizona, United States
  • Site 68
    Tucson, Arizona, United States
  • Site 5
    Jonesboro, Arkansas, United States
  • Site 88
    Little Rock, Arkansas, United States
  • Site 95
    Little Rock, Arkansas, United States
  • Site 104
    Carmichael, California, United States
  • Site 42
    Encinitas, California, United States
  • Site 21
    San Diego, California, United States
  • Site 37
    San Diego, California, United States
  • Site 78
    San Diego, California, United States
  • Site 82
    San Diego, California, United States
  • Site 69
    Avon, Connecticut, United States
  • Site 58
    Bridgeport, Connecticut, United States
  • Site 3
    Groton, Connecticut, United States
  • Site 72
    Hartford, Connecticut, United States
  • Site 54
    New Britain, Connecticut, United States
  • Site 79
    Southport, Connecticut, United States
  • Site 18
    Waterbury, Connecticut, United States
  • Site 97
    West Hartford, Connecticut, United States
  • Site 35
    Aventura, Florida, United States
  • Site 36
    Aventura, Florida, United States
  • Site 105
    Clearwater, Florida, United States
  • Site 49
    Clearwater, Florida, United States
  • Site 91
    Daytona Beach, Florida, United States
  • Site 57
    Melbourne, Florida, United States
  • Site 109
    Miami, Florida, United States
  • Site 39
    Pinellas Park, Florida, United States
  • Site 107
    Spring Hill, Florida, United States
  • Site 100
    Tampa, Florida, United States
  • Site 77
    West Palm Beach, Florida, United States
  • Site 61
    Alpharetta, Georgia, United States
  • Site 81
    Alpharetta, Georgia, United States
  • Site 28
    Atlanta, Georgia, United States
  • Site 93
    Atlanta, Georgia, United States
  • Site 55
    Decatur, Georgia, United States
  • Site 13
    Douglasville, Georgia, United States
  • Site 87
    Powder Springs, Georgia, United States
  • Site 22
    Savannah, Georgia, United States
  • Site 99
    Savannah, Georgia, United States
  • Site 53
    Boise, Idaho, United States
  • Site 96
    Champaign, Illinois, United States
  • Site 24
    Chicago, Illinois, United States
  • Site 84
    Chicago, Illinois, United States
  • Site 26
    Peoria, Illinois, United States
  • Site 46
    Peoria, Illinois, United States
  • Site 75
    Evansville, Indiana, United States
  • Site 45
    South Bend, Indiana, United States
  • Site 8
    Waterloo, Iowa, United States
  • Site 108
    Lexington, Kentucky, United States
  • Site 50
    Baton Rouge, Louisiana, United States
  • Site 12
    Metairie, Louisiana, United States
  • Site 65
    New Orleans, Louisiana, United States
  • Site 16
    Shreveport, Louisiana, United States
  • Site 11
    Baltimore, Maryland, United States
  • Site 66
    Ann Arbor, Michigan, United States
  • Site 15
    Chaska, Minnesota, United States
  • Site 29
    Creve Coeur, Missouri, United States
  • Site 2
    Saint Louis, Missouri, United States
  • Site 67
    Saint Louis, Missouri, United States
  • Site 19
    Billings, Montana, United States
  • Site 56
    Lincoln, Nebraska, United States
  • Site 6
    Las Vegas, Nevada, United States
  • Site 40
    Reno, Nevada, United States
  • Site102
    Olean, New York, United States
  • Site 31
    Fayetteville, North Carolina, United States
  • Site 60
    New Bern, North Carolina, United States
  • Site 59
    Raleigh, North Carolina, United States
  • Site 38
    Winston-Salem, North Carolina, United States
  • Site 70
    Winston-Salem, North Carolina, United States
  • Site 85
    Winston-Salem, North Carolina, United States
  • Site 86
    Cincinnati, Ohio, United States
  • Site 101
    Edmond, Oklahoma, United States
  • Site 89
    Eugene, Oregon, United States
  • Site 111
    Medford, Oregon, United States
  • Site 64
    Portland, Oregon, United States
  • Site 113
    Erie, Pennsylvania, United States
  • Site 98
    Pottstown, Pennsylvania, United States
  • Site 33
    Greenville, South Carolina, United States
  • Site 9
    Chattanooga, Tennessee, United States
  • Site 92
    Memphis, Tennessee, United States
  • Site 76
    Nashville, Tennessee, United States
  • Site 83
    Carrollton, Texas, United States
  • Site 17
    Conroe, Texas, United States
  • Site 23
    Corpus Christi, Texas, United States
  • Site 25
    Corpus Christi, Texas, United States
  • Site 30
    Dallas, Texas, United States
  • Site 90
    Dallas, Texas, United States
  • Site 10
    Houston, Texas, United States
  • Site 110
    Houston, Texas, United States
  • Site 14
    Houston, Texas, United States
  • Site 27
    Houston, Texas, United States
  • Site 48
    Houston, Texas, United States
  • Site 51
    Houston, Texas, United States
  • Site 71
    Houston, Texas, United States
  • Site 73
    Houston, Texas, United States
  • Site 43
    San Antonio, Texas, United States
  • Site 62
    San Antonio, Texas, United States

Showing the first 100 of 109 sites. Choose a country and city above to see the rest.

07

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2004 to primary completion in Sep 2005, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
StartActual
Dec 2, 2004
Primary completionActual
Sep 6, 2005
CompletionActual
Sep 6, 2005
Last update
Sep 13, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 13, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00160173
Lead sponsor
ASCEND Therapeutics
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Dec 2, 2004
Primary completion
Sep 6, 2005
Completion
Sep 6, 2005
Last update
Sep 13, 2022

Study contacts

Global Clinical Director Solvay
study director · Solvay Pharmaceuticals
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion